Free tool
FAERS Monitor: Varubi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206500 or its brand name (Varubi, Rolapitant Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
539
Serious
418
78% of reports
Hospitalization
115
Death reported
164
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death143
- nausea79
- fatigue51
- infusion related reaction40
- dyspnoea34
- decreased appetite33
- flushing32
- diarrhoea30
- thrombocytopenia29
- dehydration22
- vomiting22
- chest discomfort21
- anaemia20
- back pain19
- weight decreased17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 17 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 94 |
| 2017 | 111 |
| 2018 | 96 |
| 2019 | 60 |
| 2020 | 116 |
| 2021 | 18 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,620 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 40 | 23.6 | 17.5 | 844 |
| flushingSignal | 32 | 12.3 | 8.8 | 322 |
| thrombocytopeniaSignal | 29 | 10.1 | 7.1 | 231 |
| chest discomfortSignal | 21 | 8.0 | 5.3 | 122 |
| deathSignal | 143 | 6.5 | 5.6 | 685 |
| dehydrationSignal | 22 | 6.4 | 4.3 | 96 |
| decreased appetiteSignal | 33 | 5.5 | 4.0 | 120 |
| anaemiaSignal | 20 | 4.1 | 2.7 | 44 |
| nauseaSignal | 79 | 3.9 | 3.2 | 174 |
| back painSignal | 19 | 3.2 | 2.1 | 27 |
| fatigueSignal | 51 | 2.6 | 2.0 | 49 |
| weight decreasedSignal | 17 | 2.4 | 1.5 | 12 |
| dyspnoeaSignal | 34 | 2.3 | 1.7 | 26 |
| vomiting | 22 | 1.8 | 1.2 | 8 |
| diarrhoea | 30 | 1.8 | 1.3 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.